文献速递肺血管病与心包/心肌炎

AMPK/USP10环路激活ACE2对肺动脉高压的意义

AMPK/USP10 loop activation of ACE2: implications for pulmonary hypertension.
PubMed 文献 · Eur Heart J · 2026-07-28

本研究探讨肺内皮中USP10与AMPK正反馈环路对肺动脉高压的保护作用。在人类特发性PAH和啮齿类PH模型中USP10水平降低,激活该环路可增加ACE2磷酸化与去泛素化,维持ACE2稳态和肺血管通畅。利拉鲁肽给药可模拟内皮特异性USP10转基因小鼠的PH减轻效应,部分通过激活肺内皮AMPK/USP10环路实现。

要点

  • 肺内皮USP10在人类IPAH和啮齿类PH中表达降低。
  • AMPK/USP10环路通过促进ACE2 Ser-680磷酸化和Lys-788去泛素化维持ACE2水平。
  • GLP-1受体激动剂利拉鲁肽可激活该环路并减轻啮齿类PH。

核心结论

  • 遗传或药物(GLP-1受体激动剂)干预AMPK/USP10环路可提升肺内皮ACE2水平,对人类PAH和啮齿类PH产生保护作用。

研究设计与样本

  • 采用计算机模拟数据分析和体外培养细胞实验,研究USP10在人类IPAH和啮齿类PH中的作用及AMPK/USP10正反馈环路机制。
  • 使用内皮细胞特异性USP10转基因小鼠和接受利拉鲁肽给药的小鼠探索AMPK/USP10环路减轻啮齿类PH的疗效。

主要发现

  • USP10水平在人类IPAH和啮齿类PH的肺内皮中降低。
  • AMPK/USP10环路激活增加ACE2 Ser-680磷酸化和Lys-788去泛素化,有助于维持ACE2稳态水平和肺血管通畅。
  • 利拉鲁肽给药小鼠部分通过激活肺内皮AMPK/USP10环路,表现出与内皮特异性USP10转基因小鼠相似的PH减轻。

临床怎么用

  • GLP-1受体激动剂可能通过激活肺内皮AMPK/USP10环路提升ACE2水平,为缓解PAH提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The intricate balance between angiotensin-converting enzyme 1 (ACE1) and 2 (ACE2) in the pulmonary vasculature is pivotal for the pathogenesis of pulmonary arterial hypertension (PAH). Catalysing the K48-linked deubiquitination, ubiquitin carboxyl-terminal hydrolase 10 (USP10) is involved in tumour suppression, autophagy, and cell proliferation. This study aims to determine whether a positive feedback loop of USP10 and AMP-activated protein kinase (AMPK) in pulmonary endothelium is protective against PAH. METHODS: In silico data analyses and in vitro culture cell experiments were used to investigate the role of USP10 in human idiopathic PAH (IPAH) and rodent pulmonary hypertension (PH) as well as the underlying mechanism involving a positive feedback loop of AMPK and USP10 in lung endothelium. Endothelial cell (EC)-specific USP10 transgenic (Tg) mice and mice administered liraglutide were used to explore the efficacy of the AMPK/USP10 loop in mitigating PH in rodents. RESULTS: USP10 level was decreased in the lung endothelium of human IPAH and rodent PH. AMPK/USP10 loop activation increased ACE2 Ser-680 phosphorylation and Lys-788 deubiquitination, thus contributing to the homeostatic level of ACE2 and lung vascular patency. Mice with liraglutide administration phenocopied the mitigated PH in EC-specific USP10 Tg mice, in part because of the activated AMPK/USP10 loop in the pulmonary endothelium. CONCLUSIONS: Genetic or pharmacologic [via glucagon-like peptide-1 receptor agonists (GLP-1 RAs)] interventions in the AMPK/USP10 loop can augment ACE2 level in lung endothelium. This type of ACE2 enhancement garners protection against PAH in humans and PH in rodents, which provides a rationale for using GLP-1 RAs to alleviate PAH.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Chen Z, Ge D, Li X, et al. AMPK/USP10 loop activation of ACE2: implications for pulmonary hypertension. Eur Heart J. 2026. PMID: 42517561. doi:10.1093/eurheartj/ehag568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。